Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-08-24 Share Issue/Capital Cha…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
111年8月變更登記
Share Issue/Capital Change Classification · 95% confidence The document is a brief disclosure from a listed company (美時) providing details about its capital stock, including authorized capital, paid-in capital, and changes such as cancellation of restricted employee shares. The document length is only 854 characters, indicating it is a short announcement rather than a full report. There is no financial statement, management discussion, or detailed analysis present. The content focuses on capital stock details and registration approvals, which aligns with announcements about share capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA).
2022-08-24 Chinese
本公司收回已發行限制員工權利新股註銷減資變更登記完成
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory announcement from a listed company (1795 美時) regarding the completion of a capital reduction registration after the cancellation of restricted employee shares. It includes specific details about the capital amount before and after reduction, share counts, and net asset value per share. The document is short (921 characters) and focuses on a capital structure change rather than a full financial report. There is no indication of a full annual or interim report, audit report, or earnings release. The content fits the description of a Share Issue/Capital Change announcement, which covers changes in capital structure such as share cancellations and capital reductions.
2022-08-24 Chinese
111年08月僑外投資持股
Major Shareholding Notification Classification · 95% confidence The document is a statistical report on shareholding by overseas and mainland China investors, detailing the number of shares held before and after certain dates, and explaining discrepancies. It includes specific shareholding figures and changes related to foreign investors. There is no indication of it being an announcement of a report, nor does it contain financial statements or management commentary. It is a notification about major shareholding levels and changes, fitting the definition of a Major Shareholding Notification (MRQ). The document length is short but contains substantive data on shareholding changes, not just a brief announcement or certification.
2022-08-24 Chinese
係因本公司有價證券於集中交易市場達公布注意交易資訊標 準，故公布相關財務業務等重大訊息，以利投資人區別瞭解
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (1795 美時) disclosing significant financial and business information due to securities trading reaching a threshold requiring disclosure. It includes recent monthly and quarterly revenue and profit figures, percentage changes compared to prior periods, and explanations for performance changes. The document references compliance with Taiwan Stock Exchange regulations and directs readers to the public information observatory for complete financial data. The document length is short (1568 characters) and it does not contain full financial statements or detailed analysis, but rather a summary of recent financial performance and related disclosures. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement of financial information without being a full financial report like an Interim Report or Annual Report.
2022-08-22 Chinese
澄清經濟日報111/08/17報導
Regulatory Filings Classification · 95% confidence The document is a short announcement clarifying a media report about the company's financial performance and operations. It explicitly states that the company did not prepare financial forecasts and that actual financial results are available on the public information observatory for investors. The document is only 712 characters long and serves to clarify information rather than provide detailed financial data or reports. It does not contain financial statements, management discussion, or any detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS), which is a general regulatory announcement or clarification that does not fit into other specific categories.
2022-08-17 Chinese
111年第2季海外子公司投資
Interim / Quarterly Report Classification · 85% confidence The document contains detailed financial data related to investments in overseas subsidiaries, including shareholding percentages, original investment amounts, investment balances, and recognized investment gains or losses. The data is presented in a tabular format with notes explaining accounting treatments, consistent with financial reporting standards. The document length is 2258 characters, which is relatively short but contains substantive financial data rather than just an announcement or certification. There is no indication that this is a full annual report or an interim report for a shorter period, but the data corresponds to a quarterly or semi-annual period (111年2季, which translates to the second quarter of the 111th year in the Taiwanese calendar, equivalent to 2022). Given the presence of detailed financial figures and investment performance for a specific quarter, this aligns best with an Interim / Quarterly Report (IR). H1 2022
2022-08-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.